XmAb18087

XmAb18087 · Xencor, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XmAb18087, covering 2023-04-20 to 2023-04-20. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer [Phase 1, Phase 2]

See pricing